title: Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression.
abstract: At the CC (beta) chemokine receptor 2 (CCR2) and CCR5 loci, combinations of common single-nucleotide polymorphisms (SNPs) and a 32-bp deletion (Delta32) form nine stable haplotypes (designated A through G*2). The distribution of these CCR2-CCR5 haplotypes was examined among 703 participants in the Multicenter AIDS Cohort Study (MACS), the District of Columbia Gay (DCG) Study, and the San Francisco Men's Health Study (SFMHS). Highly exposed and persistently seronegative (HEPS; n = 90) Caucasian men from MACS more frequently carried heterozygous G*2 (Delta32) genotypes (especially A/G*2) and less frequently carried the homozygous E/E genotype compared with 469 Caucasian seroconverters (SCs) from the same cohort (P = 0.004 to 0.042). Among 341 MACS Caucasian SCs with 6- to 12-month human immunodeficiency virus type 1 (HIV-1) seroconversion intervals and no potent antiretroviral therapy, mean plasma HIV-1 RNA level during the initial 42 months after seroconversion was higher in carriers of the E/E genotype and lower in those with the 64I-bearing haplotype F*2 or the Delta32-bearing haplotype G*2 (and especially genotypes A/G*2 and F*2/G*2). A multivariable model containing these CCR markers showed significant composite effects on HIV-1 RNA at each of four postconversion intervals (P = 0.0004 to 0.050). In other models using time to AIDS as the endpoint, the same markers showed more modest contributions (P = 0.08 to 0.24) to differential outcome during 11.5 years of follow-up. Broadly consistent findings in the larger MACS Caucasian SCs and the smaller groups of MACS African-American SCs and the DCG and SFMHS Caucasian SCs indicate that specific CCR2-CCR5 haplotypes or genotypes mediate initial acquisition of HIV-1 infection, early host-virus equilibration, and subsequent pathogenesis.
authors.affiliation: Division of Geographic Medicine, Department of Medicine, School of Medicine, Program in Epidemiology of Infection and Immunity, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
authors.forename: Jianming
authors.initials: J
authors.lastname: Tang
authors.forename: Brent
authors.initials: B
authors.lastname: Shelton
authors.forename: Nina J
authors.initials: NJ
authors.lastname: Makhatadze
authors.forename: Yuting
authors.initials: Y
authors.lastname: Zhang
authors.forename: Margaret
authors.initials: M
authors.lastname: Schaen
authors.forename: Leslie G
authors.initials: LG
authors.lastname: Louie
authors.forename: James J
authors.initials: JJ
authors.lastname: Goedert
authors.forename: Eric C
authors.initials: EC
authors.lastname: Seaberg
authors.forename: Joseph B
authors.initials: JB
authors.lastname: Margolick
authors.forename: John
authors.initials: J
authors.lastname: Mellors
authors.forename: Richard A
authors.initials: RA
authors.lastname: Kaslow
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000175:diagnosis / Q000235:genetics / Q000821:virology; D000328:Adult; D044383:Black People / Q000235:genetics; D016009:Chi-Square Distribution; D018450:Disease Progression; D006679:HIV Seropositivity / Q000097:blood / Q000175:diagnosis / Q000235:genetics* / Q000821:virology; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology / Q000502:physiology*; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D010641:Phenotype; D011379:Prognosis; D012367:RNA, Viral / Q000097:blood*; D054390:Receptors, CCR2; D019713:Receptors, CCR5 / Q000235:genetics*; D019707:Receptors, Chemokine / Q000235:genetics*; D013997:Time Factors; D016896:Treatment Outcome; D044465:White People / Q000235:genetics; D001741:Black or African American
chemical_list: C515334:CCR2 protein, human; D012367:RNA, Viral; D054390:Receptors, CCR2; D019713:Receptors, CCR5; D019707:Receptors, Chemokine